Palomino director buys 12,500 shares at $4.00
Palomino Laboratories Inc. director Steven Denbaars made an open-market purchase of 12,500 shares of Common Stock at $4.00 per share on April 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Palomino Laboratories Inc. director Steven Denbaars made an open-market purchase of 12,500 shares of Common Stock at $4.00 per share on April 20, 2026. After this transaction, he directly owns 1,762,500 shares of the company’s Common Stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 12,500 | $4.00 | $50K |
Key Figures
Key Terms
open-market purchase financial
Common Stock financial
non-derivative financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Steven Denbaars report at Palomino Laboratories (PALX)?
What was the price paid in the Palomino Laboratories (PALX) insider purchase?
Was the Palomino Laboratories (PALX) insider trade a buy or a sell?
Is Steven Denbaars’ ownership in Palomino Laboratories (PALX) direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.